Skip to main content

Advertisement

Log in

Treatment options in emerging mold infections

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Although Zygomycetes, Fusarium spp, and Scedosporium spp are far less frequent causes of invasive fungal disease than Aspergillus and Candida, they are emerging. These types of infections in severely immunocompromised patients have a common feature: a poor clinical response to antifungal therapy. Infection is usually airborne, although local infections in cases of skin trauma are also possible. These fungi are resistant to some common antifungal agents; therefore, surgical debridement of the necrotic tissue, when possible, should be combined with specific systemic antifungal treatment in immunocompromised patients. In the absence of randomized clinical trials, most experience in the treatment of these infections is with amphotericin B. Experience with new antifungal agents is still limited, and recovery from neutropenia remains the main predictor of a favorable outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Nucci M, Marr KA, Queiroz-Telles F, et al.: Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38:1237–1242.

    Article  PubMed  Google Scholar 

  2. Singh J, Rimek D, Kappe R: In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005, 48:246–250.

    Article  PubMed  CAS  Google Scholar 

  3. Sabatelli F, Patel R, Mann PA, et al.: In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006, 50:2009–2015.

    Article  PubMed  CAS  Google Scholar 

  4. Eisen DP, Robson J: Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses 2004, 47:159–162.

    Article  PubMed  CAS  Google Scholar 

  5. Dannaoui E, Meletiadis J, Mouton JW, et al.: In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003, 51:45–52.

    Article  PubMed  CAS  Google Scholar 

  6. Torres-Narbona M, Guinea J, Martinez-Alarcón J, et al.: In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 2007, 51:1126–1129.

    Article  PubMed  CAS  Google Scholar 

  7. Guembe M, Guinea J, Peláez T, et al.: Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother 2007, 51:3457–3458.

    Article  PubMed  CAS  Google Scholar 

  8. Guinea J, Peláez T, Recio S, et al.: In vitro antifungal activity of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008, 52:1396–1400.

    Article  PubMed  CAS  Google Scholar 

  9. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV: Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851–856.

    Article  PubMed  CAS  Google Scholar 

  10. Prabhu RM, Patel R: Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004, 10(Suppl 1):31–47.

    Article  PubMed  Google Scholar 

  11. Gleissner B, Schilling A, Anagnostopolous I, et al.: Improved outcome of zygomycosis in patients with hematological diseases? Leuk Lymphoma 2004, 45:1351–1360.

    Article  PubMed  CAS  Google Scholar 

  12. Morduchowicz G, Shmueli D, Shapira Z, et al.: Rhinocerebral mucormycosis in renal transplant recipients: report of three cases and review of the literature. Rev Infect Dis 1986, 8:441–446.

    PubMed  CAS  Google Scholar 

  13. Trifilio S, Singhal S, Williams S, et al.: Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007, 40:451–456.

    Article  PubMed  CAS  Google Scholar 

  14. Oren I: Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005, 40:770–771.

    Article  PubMed  Google Scholar 

  15. Kontoyiannis DP, Lionakis MS, Lewis RE, et al.: Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005, 191:1350–1360.

    Article  PubMed  Google Scholar 

  16. Vigouroux S, Morin O, Moreau P, et al.: Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005, 40:e35–e37.

    Article  PubMed  Google Scholar 

  17. Greenberg RN, Mullane K, van Burik JA, et al.: Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006, 50:126–133.

    Article  PubMed  CAS  Google Scholar 

  18. van Burik JA, Hare RS, Solomon HF, et al.: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61–e65.

    Article  PubMed  Google Scholar 

  19. Rickerts V, Atta J, Herrmann S, et al.: Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses 2006, 49(Suppl 1):27–30.

    Article  PubMed  Google Scholar 

  20. John BV, Chamilos G, Kontoyiannis DP: Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect 2005, 11:515–517.

    Article  PubMed  CAS  Google Scholar 

  21. Nelson PE, Dignani MC, Anaissie EJ: Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994, 7:479–504.

    PubMed  CAS  Google Scholar 

  22. Anaissie EJ, Kuchar RT, Rex JH, et al.: Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33:1871–1878.

    Article  PubMed  CAS  Google Scholar 

  23. Nucci M, Anaissie E: Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007, 20:695–704.

    Article  PubMed  CAS  Google Scholar 

  24. Espinel-Ingroff A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003, 20:121–136.

    PubMed  Google Scholar 

  25. García-Effrón G, Gómez-López A, Mellado E, et al.: In vitro activity of terbinafine against medically important non-dermatophyte species of filamentous fungi. J Antimicrob Chemother 2004, 53:1086–1089.

    Article  PubMed  Google Scholar 

  26. Rao SK, Lam PT, Li EY, et al.: A case series of contact lensassociated Fusarium keratitis in Hong Kong. Cornea 2007, 26:1205–1209.

    PubMed  Google Scholar 

  27. Nucci M, Anaissie EJ, Queiroz-Telles F, et al.: Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003, 98:315–319.

    Article  PubMed  Google Scholar 

  28. Perfect JR: Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005, 40(Suppl 6):S401–S408.

    Article  PubMed  CAS  Google Scholar 

  29. Perfect JR, Marr KA, Walsh TJ, et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122–1131.

    Article  PubMed  CAS  Google Scholar 

  30. Raad II, Hachem RY, Herbrecht R, et al.: Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006, 42:1398–1403.

    Article  PubMed  CAS  Google Scholar 

  31. Husain S, Muñoz P, Forrest G, et al.: Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005, 40:89–99.

    Article  PubMed  Google Scholar 

  32. Revankar SG, Patterson JE, Sutton DA, et al.: Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002, 34:467–476.

    Article  PubMed  Google Scholar 

  33. Berenguer J, Rodríiguez-Tudela JL, Richard C, et al.: Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 1997, 76:256–265.

    Article  CAS  Google Scholar 

  34. Guerrero A, Torres P, Durán MT, et al.: Airborne outbreak of nosocomial Scedosporium prolificans infection. Lancet 2001, 357:1267–1268.

    Article  PubMed  CAS  Google Scholar 

  35. Husain S, Alexander BD, Muñoz P, et al.: Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003, 37:221–229.

    Article  PubMed  Google Scholar 

  36. Ruchel R, Wilichowski E: Cerebral Pseudallescheria mycosis after near-drowning. Mycoses 1995, 38:473–475.

    Article  PubMed  CAS  Google Scholar 

  37. Safdar A, Papadopoulos EB, Young JW: Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiosis and recent advances in antifungal therapy. Transpl Infect Dis 2002, 4:212–217.

    PubMed  CAS  Google Scholar 

  38. Espinel-Ingroff A, Johnson E, Hockey H, Troke P: Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J Antimicrob Chemother 2008, 61:616–620.

    Article  PubMed  CAS  Google Scholar 

  39. Cortez KJ, Roilides E, Quiroz-Telles F, et al.: Infections caused by Scedosporium spp. Clin Microbiol Rev 2008, 21:157–197.

    Article  PubMed  CAS  Google Scholar 

  40. Carrillo AJ, Guarro J: In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001, 45:2151–2153.

    Article  PubMed  CAS  Google Scholar 

  41. Meletiadis J, Meis JF, Mouton JW, et al.: In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002, 46:62–68.

    Article  PubMed  CAS  Google Scholar 

  42. Meletiadis J, Mouton JW, Meis JF, Verweij PE: In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003, 47:106–117.

    Article  PubMed  CAS  Google Scholar 

  43. Afeltra J, Dannaoui E, Meis JF, et al.: In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother 2002, 46:3323–3326.

    Article  PubMed  CAS  Google Scholar 

  44. Heyn K, Tredup A, Salvenmoser S, Muller FM: Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005, 49:5157–5159.

    Article  PubMed  CAS  Google Scholar 

  45. Reimann D, Bussemaker E, Gross P: Successful treatment due to vacuum seal technique of a severe Scedosporium apiospermum skin infection in a renal transplant recipient. Nephrol Dial Transplant 2004, 19:245–248.

    Article  PubMed  Google Scholar 

  46. Muñoz P, Singh N, Bouza E: Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis 2006, 19:365–370.

    Article  PubMed  CAS  Google Scholar 

  47. Barbaric D, Shaw PJ: Scedosporium infection in immunocompromised patients: successful use of liposomal amphotericin B and itraconazole. Med Pediatr Oncol 2001, 37:122–125.

    Article  PubMed  CAS  Google Scholar 

  48. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ: Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002, 34:1648–1650.

    Article  PubMed  Google Scholar 

  49. Gil-Lamaignere C, Roilides E, Mosquera J, et al.: Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother 2002, 46:2234–2237.

    Article  PubMed  CAS  Google Scholar 

  50. Ortoneda M, Capilla J, Pujol I, et al.: Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 2002, 49:525–529.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Patricia Muñoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muñoz, P., Guinea, J. & Bouza, E. Treatment options in emerging mold infections. Curr Infect Dis Rep 10, 473–479 (2008). https://doi.org/10.1007/s11908-008-0077-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-008-0077-9

Keywords

Navigation